HIV and bone disease

Area of Science:

• Bone metabolism and osteoporosis
• Infectious diseases and immunology

Background:

• Improved human immunodeficiency virus (HIV) management has reduced mortality.
• Long-term complications, including bone disease, are now a significant concern for HIV-infected individuals.
• Reduced bone mineral density (BMD) and increased fracture incidence are observed in HIV-positive populations.

Purpose of the Study:

• To highlight the increasing recognition of bone disease as a long-term complication in HIV management.
• To discuss potential causes of bone disease in HIV-infected individuals, including risk factors, direct HIV effects, and antiretroviral therapy (ART).
• To emphasize the need for improved assessment strategies and the development of specific preventative and therapeutic interventions for bone disease in HIV.

Main Methods:

• Review of current understanding of bone disease in HIV.
• Discussion of potential contributing factors to reduced BMD and fracture risk.
• Analysis of existing data on treatment strategies.

Main Results:

• HIV-positive individuals exhibit increased prevalence of reduced BMD and fracture incidence compared to HIV-negative controls.
• Multiple factors contribute to bone disease, including pre-existing risk factors, HIV infection itself, and ART.
• Current assessment of bone disease and fracture risk in HIV is inadequate, lacking clear guidance.

Conclusions:

• Bone disease is a critical long-term complication requiring attention in HIV care.
• Development of specific diagnostic and therapeutic strategies for bone health in HIV is essential.
• Further research, including larger, longer studies on bisphosphonates, vitamin D, and calcium, is needed to evaluate treatment efficacy, safety, and cost-effectiveness.